Therapeutics News and Research

RSS

Fondation Leducq grants $6M to cardiovascular scientists to help advance cardiac regeneration therapeutics

The Fondation Leducq in Paris, France, dedicated to improving human health through international efforts to combat cardiovascular disease, awarded a $6 million grant award to a new global research network of cardiovascular scientists which includes three researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.

2 Jul 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

Edge Therapeutics announced today positive preliminary results from the first human use of EG-1962, the Company's novel bioabsorbable nimodipine microparticle formulation for the prevention of delayed cerebral ischemia, a life-threatening complication of subarachnoid hemorrhage, typically resulting from a ruptured brain aneurysm or traumatic brain injury.

27 Jun 2013

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.

27 Jun 2013

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

MorphoSys AG and Celgene Corporation today announced an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

27 Jun 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

Promising approach to reduce risk of hypoglycemia in diabetes shows positive results

People with type 1 diabetes who rely on insulin injections to control their blood sugar levels are at risk for life-threatening hypoglycemic events in which their blood glucose levels drop dangerously low.

25 Jun 2013

Study questions the beneficial effects of polyphenols on combating cardiovascular disease

Eating fruit or having a glass of red wine is seen as offering health benefits. The benefits are often pinned on polyphenols, natural chemicals—found in foods—referred to as flavonoids and phenolic acids, but also fragments of food proteins called peptides.

25 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

TGen, Ventana sign research agreement to develop diagnostic markers for cancer

The Translational Genomics Research Institute and Ventana Medical Systems, Inc., a member of the Roche Group, today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer.

25 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

PTC Therapeutics announces pricing of its initial public offering

PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC.

20 Jun 2013

NUS researchers develop highly realistic 3-D tumor model to track progress of drug therapy

A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.

20 Jun 2013

Staph-killing compound may be effective against osteomyelitis

Osteomyelitis - a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria - is particularly challenging to treat.

20 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Therapeutics News and Research

Fondation Leducq grants $6M to cardiovascular scientists to help advance cardiac regeneration therapeutics

Brisdelle receives FDA approval to treat hot flashes associated with menopause

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Promising approach to reduce risk of hypoglycemia in diabetes shows positive results

Study questions the beneficial effects of polyphenols on combating cardiovascular disease

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

TGen, Ventana sign research agreement to develop diagnostic markers for cancer

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

PTC Therapeutics announces pricing of its initial public offering

NUS researchers develop highly realistic 3-D tumor model to track progress of drug therapy

Staph-killing compound may be effective against osteomyelitis

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News